18.66
price up icon1.58%   0.29
after-market Dopo l'orario di chiusura: 18.47 -0.19 -1.02%
loading
Precedente Chiudi:
$18.37
Aprire:
$18.47
Volume 24 ore:
32,606
Relative Volume:
0.57
Capitalizzazione di mercato:
$929.65M
Reddito:
-
Utile/perdita netta:
$-143.59M
Rapporto P/E:
-6.6086
EPS:
-2.8236
Flusso di cassa netto:
$-119.47M
1 W Prestazione:
+9.38%
1M Prestazione:
+30.67%
6M Prestazione:
-19.60%
1 anno Prestazione:
-17.43%
Intervallo 1D:
Value
$18.10
$19.07
Intervallo di 1 settimana:
Value
$16.68
$19.07
Portata 52W:
Value
$11.51
$25.50

Pharvaris Nv Stock (PHVS) Company Profile

Name
Nome
Pharvaris Nv
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
108
Name
Cinguettio
Name
Prossima data di guadagno
2024-08-05
Name
Ultimi documenti SEC
Name
PHVS's Discussions on Twitter

Confronta PHVS con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
PHVS
Pharvaris Nv
18.66 929.65M 0 -143.59M -119.47M -2.8236
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
500.19 127.64B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
603.58 65.95B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
656.65 37.92B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
273.55 32.98B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
254.16 26.92B 3.81B -644.79M -669.77M -6.24

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-04-29 Iniziato Cantor Fitzgerald Overweight
2023-09-25 Iniziato Wedbush Outperform
2023-08-15 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-10-05 Iniziato Bryan Garnier Buy
2022-09-13 Ripresa JMP Securities Mkt Outperform
2022-08-23 Downgrade Morgan Stanley Overweight → Equal-Weight
2022-08-22 Downgrade BofA Securities Neutral → Underperform
2022-05-25 Iniziato JMP Securities Mkt Outperform
2021-03-02 Iniziato BofA Securities Neutral
2021-03-02 Iniziato Morgan Stanley Overweight
2021-03-02 Iniziato Oppenheimer Outperform
2021-03-02 Iniziato SVB Leerink Outperform
Mostra tutto

Pharvaris Nv Borsa (PHVS) Ultime notizie

pulisher
May 03, 2025

When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com

May 03, 2025
pulisher
May 02, 2025

Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World

May 02, 2025
pulisher
May 02, 2025

Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 02, 2025
pulisher
Apr 29, 2025

Cantor Fitzgerald Initiates Pharvaris at Overweight With $28 Price Target - marketscreener.com

Apr 29, 2025
pulisher
Apr 23, 2025

JMP reiterates Pharvaris stock with $55 target, positive outlook By Investing.com - Investing.com UK

Apr 23, 2025
pulisher
Apr 18, 2025

Where are the Opportunities in (PHVS) - news.stocktradersdaily.com

Apr 18, 2025
pulisher
Apr 12, 2025

Pharvaris (NASDAQ:PHVS) Trading Down 8.4%Here's Why - MarketBeat

Apr 12, 2025
pulisher
Apr 11, 2025

5,800 Shares in Pharvaris (NASDAQ:PHVS) Acquired by KLP Kapitalforvaltning AS - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

What is Leerink Partnrs’ Estimate for Pharvaris Q1 Earnings? - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

Wedbush Issues Pessimistic Forecast for Pharvaris Earnings - Defense World

Apr 11, 2025
pulisher
Apr 10, 2025

What is Wedbush’s Forecast for Pharvaris FY2029 Earnings? - Defense World

Apr 10, 2025
pulisher
Apr 08, 2025

Pharvaris NV reports results for the quarter ended December 31Earnings Summary - TradingView

Apr 08, 2025
pulisher
Apr 07, 2025

Pharvaris Reports 2024 Financial Results and Business Progress - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Pharvaris Accelerates HAE Drug Development: Phase 3 Trial Fully Enrolled, €281M War Chest - Stock Titan

Apr 07, 2025
pulisher
Apr 02, 2025

Pharvaris (PHVS) Projected to Post Earnings on Wednesday - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

(PHVS) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 02, 2025
pulisher
Apr 01, 2025

Pharvaris Says EU Orphan Designation Received for Deucrictibant - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Major EU Breakthrough: Pharvaris' Angioedema Drug Gains Coveted Orphan Status - Stock Titan

Apr 01, 2025
pulisher
Mar 12, 2025

(PHVS) Technical Data - news.stocktradersdaily.com

Mar 12, 2025
pulisher
Mar 03, 2025

Can Pharvaris Impress Investors at Upcoming Leerink Conference? - StockTitan

Mar 03, 2025
pulisher
Mar 01, 2025

How to Take Advantage of moves in (PHVS) - Stock Traders Daily

Mar 01, 2025
pulisher
Feb 26, 2025

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth - Yahoo Finance

Feb 26, 2025
pulisher
Feb 18, 2025

(PHVS) Trading Report - Stock Traders Daily

Feb 18, 2025
pulisher
Feb 17, 2025

Pharvaris (NASDAQ:PHVS) Sees Significant Increase in Short Interest - MarketBeat

Feb 17, 2025
pulisher
Feb 13, 2025

Pharvaris (NASDAQ:PHVS) Sees Strong Trading VolumeWhat's Next? - MarketBeat

Feb 13, 2025
pulisher
Feb 11, 2025

Pharvaris (NASDAQ:PHVS) Shares Gap DownWhat's Next? - MarketBeat

Feb 11, 2025
pulisher
Feb 08, 2025

(PHVS) Investment Analysis - Stock Traders Daily

Feb 08, 2025
pulisher
Feb 04, 2025

Pharvaris (NASDAQ:PHVS) Price Target Raised to $55.00 - MarketBeat

Feb 04, 2025
pulisher
Jan 24, 2025

Barclays PLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World

Jan 24, 2025
pulisher
Jan 23, 2025

Why Is Andreas Halvorsen Bullish On Pharvaris N.V. (PHVS) Now? - Insider Monkey

Jan 23, 2025
pulisher
Jan 23, 2025

FY2026 EPS Estimates for Pharvaris Decreased by Analyst - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Leerink Partnrs Brokers Cut Earnings Estimates for Pharvaris - MarketBeat

Jan 22, 2025
pulisher
Jan 22, 2025

Billionaire Andreas Halvorsen’s Top 15 Long-Term Stock Picks - Insider Monkey

Jan 22, 2025
pulisher
Jan 21, 2025

Pharvaris (NASDAQ:PHVS) Trading Up 5.3%What's Next? - MarketBeat

Jan 21, 2025
pulisher
Jan 17, 2025

How To Trade (PHVS) - Stock Traders Daily

Jan 17, 2025
pulisher
Jan 13, 2025

Pharvaris (NASDAQ:PHVS) Stock Price Down 11.7%Here's Why - MarketBeat

Jan 13, 2025
pulisher
Jan 13, 2025

Pharvaris Advances Phase 3 HAE Programs, Expands Pipeline Into Acquired Angioedema Treatment - StockTitan

Jan 13, 2025
pulisher
Jan 12, 2025

Geode Capital Management LLC Boosts Holdings in Pharvaris (NASDAQ:PHVS) - Defense World

Jan 12, 2025
pulisher
Jan 09, 2025

Barclays PLC Takes Position in Pharvaris (NASDAQ:PHVS) - Defense World

Jan 09, 2025
pulisher
Jan 06, 2025

(PHVS) Long Term Investment Analysis - Stock Traders Daily

Jan 06, 2025
pulisher
Jan 06, 2025

Jane Street Group LLC Makes New Investment in Pharvaris (NASDAQ:PHVS) - Defense World

Jan 06, 2025
pulisher
Jan 06, 2025

Jane Street Group LLC Acquires Shares of 28,418 Pharvaris (NASDAQ:PHVS) - MarketBeat

Jan 06, 2025
pulisher
Jan 03, 2025

Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's Why - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

State Street Corp Purchases New Shares in Pharvaris (NASDAQ:PHVS) - Defense World

Jan 03, 2025
pulisher
Jan 03, 2025

53,980 Shares in Pharvaris (NASDAQ:PHVS) Bought by State Street Corp - MarketBeat

Jan 03, 2025
pulisher
Dec 31, 2024

Pharvaris (NASDAQ:PHVS) Trading Down 3.5%Here's Why - MarketBeat

Dec 31, 2024

Pharvaris Nv Azioni (PHVS) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$72.58
price up icon 0.39%
$21.55
price up icon 0.33%
$33.00
price up icon 0.33%
$28.02
price up icon 0.43%
$101.10
price down icon 3.66%
biotechnology ONC
$254.16
price down icon 0.63%
Capitalizzazione:     |  Volume (24 ore):